OXiGENE to Present at 12th Annual BIO Investor Forum Conference on October 8, 2013
September 30, 2013 12:59 ET
|
Mateon Therapeutics
SOUTH SAN FRANCISCO, Calif., Sept. 30, 2013 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, announced that...
OXiGENE Announces $5.8 Million Private Placement
September 19, 2013 12:40 ET
|
Mateon Therapeutics
SOUTH SAN FRANCISCO, Calif., Sept. 19, 2013 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, announced that it...
OXiGENE Announces Presentation at the 15th Annual Rodman & Renshaw Global Investment Conference on September 9th
September 03, 2013 16:30 ET
|
Mateon Therapeutics
SOUTH SAN FRANCISCO, Calif., Sept. 3, 2013 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, announced that...
OXiGENE Reports Second Quarter 2013 Financial Results
August 06, 2013 16:10 ET
|
Mateon Therapeutics
SOUTH SAN FRANCISCO, Calif., Aug. 6, 2013 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, reported financial...
OXiGENE Announces Second Quarter 2013 Earnings Conference Call and Webcast
July 24, 2013 16:00 ET
|
Mateon Therapeutics
SOUTH SAN FRANCISCO, Calif., July 24, 2013 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, will report second...
OXiGENE Announces Granting of Orphan Drug Status in Europe for ZYBRESTAT in Ovarian Cancer
July 18, 2013 16:11 ET
|
Mateon Therapeutics
SOUTH SAN FRANCISCO, Calif., July 18, 2013 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, announced that the...
OXIGENE Announces Publication of Final FACT Study Data in Journal Thyroid Suggest Survival Benefit of ZYBRESTAT(R) in Patients With Anaplastic Thyroid Cancer
June 10, 2013 09:00 ET
|
Mateon Therapeutics
SOUTH SAN FRANCISCO, Calif., June 10, 2013 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer, announced the...
OXiGENE Reports First Quarter 2013 Financial Results
May 06, 2013 16:00 ET
|
Mateon Therapeutics
SOUTH SAN FRANCISCO, Calif., May 6, 2013 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, reported financial...
OXiGENE Announces Completion of Enrollment of ZYBRESTAT(R) Phase 2 Ovarian Cancer Trial
April 24, 2013 16:00 ET
|
Mateon Therapeutics
SOUTH SAN FRANCISCO, Calif., April 24, 2013 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, announced that...
OXiGENE Announces First Quarter 2013 Earnings Conference Call and Webcast
April 24, 2013 06:30 ET
|
Mateon Therapeutics
SOUTH SAN FRANCISCO, Calif., April 24, 2013 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, will report first...